Trial Profile

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NRTX-1001 (Primary)
Indications Temporal-lobe-epilepsy
Focus Adverse reactions
Sponsors Neurona Therapeutics

Most Recent Events

20 Feb 2025 According to a Neurona Therapeutics media release, the company presented updated data from both the low-dose (n=5) and high-dose (n=5) cohorts of this trial at the 2024 December American Epilepsy Societys Annual Meeting.
27 Dec 2024 Protocol was amended as phase changed from phase 1 to phase 1/2.
27 Dec 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com